Drug intelligence / Profile preview

dexamethasone + hydroxychloroquine

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination of two distinct medications: dexamethasone, a glucocorticoid with anti-inflammatory properties, and hydroxychloroquine, an antimalarial and antirheumatic drug. This combination was studied during the COVID-19 pandemic, with dexamethasone showing effectiveness in reducing mortality in severe cases while hydroxychloroquine was found to provide no benefits for hospitalized patients.

Other names: Dexamethasone and Hydroxychloroquine

Targets

TLR9 (Toll-like receptor 9)TLR7 (Toll-like receptor 7)PLA2 (Phospholipase A2 group IID)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on dexamethasone + hydroxychloroquine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + hydroxychloroquine.

Explore the full profile